Deubiquitinases in cancer

Oncotarget

Volumn 6, Issue 15, 2015, Pages 12872-12889

  Wei, Rongbin ^a   Liu, Xiaodong ^b   Yu, Weixin ^b   Yang, Tianshu ^a   Cai, Wenping ^a   Liu, Junjun ^a   Huang, Xiao ^a   Xu, Guo tong ^a   Zhao, Shouliang ^b   Yang, Jianhua ^a   Liu, Shangfeng ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Cancer; Deubiquitinases; Inhibitor; Ubiquitylation

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; ANTINEOPLASTIC AGENT; AURANOFIN; BORTEZOMIB; CC 0651; DELTA12 PROSTAGLANDIN J2; DEUBIQUITINASE; DEXAMETHASONE; DOXORUBICIN; EOAI 3402143; HBX 19818; HBX 41108; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MELPHALAN; MI 219; MITOXANTRONE; ML 323; NSC 652287; P 0050429; PEVONEDISTAT; PIMOZIDE; PR 619; PROTEASOME INHIBITOR; PROTEIN P53; UBIQUITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIALININ A; WNT PROTEIN; WO 2013030218; WP 1130;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE REGULATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; HUMAN; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; ANIMAL; ENZYMOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; UBIQUITIN; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84931043317     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3671     Document Type: Article

References (207)

1. Fraile J, et al., Deubiquitinases in cancer: new functions and therapeutic options. Oncogene. 2011; 31:2373-2388.
2. Pickart CM. Mechanisms underlying ubiquitination. Annual review of biochemistry. 2001; 70:503-533.
3. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biol. 2006; 22:159-180.
4. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. EMBO reports. 2008; 9:536-542.
5. Komander D, Clague MJ, Urbé S. Breaking the chains:structure and function of the deubiquitinases. Nature reviews Molecular cell biology. 2009; 10:550-563.
6. Li W, et al., Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PloS one. 2008; 3:e1487.
7. Budhidarmo R, Nakatani Y, Day CL. RINGs hold the key to ubiquitin transfer. Trends in biochemical sciences. 2012; 37:58-65.
8. Özkan E, Yu H, Deisenhofer J. Mechanistic insight into the allosteric activation of a ubiquitin-conjugating enzyme by RING-type ubiquitin ligases. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:18890-18895.
9. Chen D, et al., Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Current cancer drug targets. 2011; 11:239.
10. Schmidt F, et al., Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells. Oncotarget. 2014.
11. Mattern MR, Wu J, Nicholson B. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2012; 1823:2014-2021.
12. Hussain S, Zhang Y, Galardy PJ. DUBs and cancer. Cell Cycle. 2009; 8:1688-1697.
13. Liu N, et al., Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget. 2014; 5:5453.
14. Turcu FER, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annual review of biochemistry. 2009; 78:363.
15. Bignell GR, et al., Identification of the familial cylindromatosis tumour-suppressor gene. Nature genetics. 2000; 25:160-165.
16. Oliveira AM, et al., Aneurysmal bone cyst: a neoplasm driven by upregulation of the USP6 oncogene. Journal of Clinical Oncology. 2006; 24:e1-e1.
17. Olazabal-Herrero A, García-Santisteban I, Rodríguez JA. Structure-function analysis of USP1: insights into the role of Ser313 phosphorylation site and the effect of cancerassociated mutations on autocleavage. Molecular cancer. 2015; 14:33.
18. Shi D, Grossman SR, Ubiquitin becomes ubiquitous in cancer:emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol Ther. 2010; 10:737-747.
19. Nicholson B, et al., Deubiquitinating enzymes as novel anticancer targets. 2007.
20. Ciechanover A, Orian A, Schwartz AL. The ubiquitin-mediated proteolytic pathway: Mode of action and clinical implications. Journal of cellular biochemistry. 2000; 77:40-51.
21. Lee MJ, et al., Trimming of ubiquitin chains by proteasomeassociated deubiquitinating enzymes. Molecular & Cellular Proteomics. 2011; 10:R110. 003871.
22. Colland F, et al., Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Molecular cancer therapeutics. 2009; 8:2286-2295.
23. Reverdy C, et al., Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chemistry & biology. 2012; 19:467-477.
24. Kapuria V, et al., Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer research. 2010; 70:9265-9276.
25. Popov N, et al., The ubiquitin-specific protease USP28 is required for MYC stability. Nature cell biology. 2007; 9:765-774.
26. Stegmeier F, et al., The tumor suppressor CYLD regulates entry into mitosis. Proceedings of the National Academy of Sciences. 2007; 104:8869-8874.
27. Jaworski J, et al., USP17 is required for clathrin mediated endocytosis of epidermal growth factor receptor. Oncotarget. 2014; 5:6964.
28. Potu H, et al., Deubiquitinases Usp9x and Usp5 control tumorigenicity and apoptotic responsiveness in malignant melanoma. Cancer Research. 2014; 74:4435-4435.
29. Chen M, Gutierrez GJ, Ze'ev AR. Ubiquitin-recognition protein Ufd1 couples the endoplasmic reticulum (ER) stress response to cell cycle control. Proceedings of the National Academy of Sciences. 2011; 108:9119-9124.
30. Faronato M, et al., The deubiquitylase USP15 stabilizes newly synthesized REST and rescues its expression at mitotic exit. Cell Cycle. 2013; 12:1964.
31. McFarlane C, et al., The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. Cancer research. 2010; 70:3329-3339.
32. Huang X, et al., Deubiquitinase USP37 Is Activated by CDK2 to Antagonize APC CDH1 and Promote S Phase Entry. Molecular cell. 2011; 42:511-523.
33. van Leuken RJ, et al., Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B. Cell Cycle. 2008; 7:2710-2719.
34. Stegmeier F, et al., Anaphase initiation is regulated by antagonistic ubiquitination and deubiquitination activities. Nature. 2007; 446:876-881.
35. Aressy B, et al., A screen for deubiquitinating enzymes involved in the g2/m checkpoint identifies usp50 as a regulator of hsp90-dependent wee1 stability. Cell Cycle. 2010; 9:3839-3846.
36. Pereg Y, et al., Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. nature cell biology. 2010; 12:400-406.
37. Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Molecular cell. 2009; 36:469-476.
38. Lu Y, et al., Identification of distinctive patterns of USP19-mediated growth regulation in normal and malignant cells. PloS one. 2011; 6:e15936.
39. van der Horst A, et al., FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP. Nature cell biology. 2006; 8:1064-1073.
40. Song MS, et al., The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature. 2008; 455:813-817.
41. Yoshida A, et al., CSN5/Jab1 controls multiple events in the mammalian cell cycle. FEBS letters. 2010; 584:4545-4552.
42. Yu H, et al., The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Molecular and cellular biology. 2010; 30:5071-5085.
43. Eletr ZM, Wilkinson KD. An emerging model for BAP1's role in regulating cell cycle progression. Cell biochemistry and biophysics. 2011; 60:3-11.
44. Nijman S, et al., The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Molecular cell. 2005; 17:331-339.
45. Guervilly JH, et al., USP1 deubiquitinase maintains phosphorylated CHK1 by limiting its DDB1-dependent degradation. Human molecular genetics. 2011; 20:2171-2181.
46. Huang TT, et al., Regulation of monoubiquitinated PCNA by DUB autocleavage. Nature cell biology. 2006; 8:341-347.
47. Murai J, et al., The USP1/UAF1 complex promotes double-strand break repair through homologous recombination. Molecular and cellular biology. 2011; 31:2462-2469.
48. Nishi R, et al., Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity. Nature cell biology. 2014.
49. Al-Hakim A, et al., The ubiquitous role of ubiquitin in the DNA damage response. DNA repair. 2010; 9:1229-1240.
50. Potu H, et al., Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway. Oncotarget. 2014; 5:5559.
51. Schoenfeld AR, et al., BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Molecular and cellular biology. 2004; 24:7444-7455.
52. Yuan J, et al., HERC2-USP20 axis regulates DNA damage checkpoint through Claspin. Nucleic acids research. 2014; :gku1034.
53. Yuan J, et al., HERC2-USP20 axis regulates DNA damage checkpoint through Claspin. Nucleic acids research. 2014; 42:13110-13121.
54. Zhang D, et al., A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell. 2006; 126:529-542.
55. Sy SM, et al., The ubiquitin specific protease USP34 promotes ubiquitin signaling at DNA double-strand breaks. Nucleic acids research. 2013; 41:8572-8580.
56. Parsons JL, et al., USP47 is a deubiquitylating enzyme that regulates base excision repair by controlling steadystate levels of DNA polymerase β. Molecular cell. 2011; 41:609-615.
57. Joo HY, et al., Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature. 2007; 449:1068-1072.
58. Clague MJ, Coulson JM, Urbé S. Deciphering histone 2A deubiquitination. Genome Biol. 2008; 9:202.
59. Atanassov BS, Koutelou E, Dent SY. The role of deubiquitinating enzymes in chromatin regulation. FEBS letters. 2011; 585:2016-2023.
60. Yu H, et al., Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proceedings of the National Academy of Sciences. 2014; 111:285-290.
61. Zhang Y. Transcriptional regulation by histone ubiquitination and deubiquitination. Genes & development. 2003; 17:2733-2740.
62. Zhu P, et al., A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Molecular cell. 2007; 27:609-621.
63. Zhang XY, et al., The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. Molecular cell. 2008; 29:102-111.
64. Feng L, Wang J, Chen J. The Lys63-specific deubiquitinating enzyme BRCC36 is regulated by two scaffold proteins localizing in different subcellular compartments. Journal of Biological Chemistry. 2010; 285:30982-30988.
65. Maertens GN, et al., Ubiquitin-specific proteases 7 and 11 modulate Polycomb regulation of the INK4a tumour suppressor. The EMBO journal. 2010; 29:2553-2565.
66. Atanassov BS, et al., Gcn5 and SAGA regulate shelterin protein turnover and telomere maintenance. Molecular cell. 2009; 35:352-364.
67. Yao T, et al., Distinct modes of regulation of the Uch37 deubiquitinating enzyme in the proteasome and in the Ino80 chromatin-remodeling complex. Molecular cell. 2008; 31:909-917.
68. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nature medicine. 2004; 10:789-799.
69. Forbes SA, et al., COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic acids research. 2010; gkq929.
70. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005; 24:2899-2908.
71. Brooks C, et al., The p53-Mdm2-HAUSP complex is involved in p53 stabilization by HAUSP. Oncogene. 2007; 26:7262-7266.
72. Kon N, et al., Inactivation of HAUSP in vivo modulates p53 function. Oncogene. 2009; 29:1270-1279.
73. Stevenson LF, et al., The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. The EMBO journal. 2007; 26:976-986.
74. Yuan J, et al., USP10 regulates p53 localization and stability by deubiquitinating p53. cell. 2010; 140:384-396.
75. Sun XX, Dai MS. Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1. 2014.
76. Dayal S, et al., Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. Journal of Biological Chemistry. 2009; 284:5030-5041.
77. Liu J, et al., JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. The EMBO journal. 2011; 30:846-858.
78. Zhang X, et al., USP4 inhibits p53 through deubiquitinating and stabilizing ARF-BP1. The EMBO journal. 2011; 30:2177-2189.
79. Prasad S, Ravindran J, Aggarwal BB. NF-κB and cancer:how intimate is this relationship. Molecular and cellular biochemistry. 2010; 336:25-37.
80. Harhaj EW, Dixit VM. Deubiquitinases in the regulation of NF-κB signaling. Cell research. 2010; 21:22-39.
81. Reiley WW, et al., Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. The Journal of experimental medicine. 2007; 204:1475-1485.
82. Massoumi R, et al., Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-κB signaling. Cell. 2006; 125:665-677.
83. Reiley W, Zhang M, Sun SC. Negative regulation of JNK signaling by the tumor suppressor CYLD. Journal of Biological Chemistry. 2004; 279:55161-55167.
84. Li L, et al., The zinc finger protein A20 targets TRAF2 to the lysosomes for degradation. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 2009; 1793:346-353.
85. Wertz IE, et al., De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature. 2004; 430:694-699.
86. Takiuchi T, et al., Suppression of LUBAC-mediated linear ubiquitination by a specific interaction between LUBAC and the deubiquitinases CYLD and OTULIN. Genes to Cells. 2014; 19:254-272.
87. Liang J, et al., MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-κB signaling. The Journal of experimental medicine. 2010; 207:2959-2973.
88. Metzig M, et al., An RNAi screen identifies USP2 as a factor required for TNF-α-induced NF-κB signaling. International Journal of Cancer. 2011; 129:607-618.
89. Fan Y, et al., USP4 targets TAK1 to downregulate TNFα-induced NF-κB activation. Cell Death & Differentiation. 2011; 18:1547-1560.
90. González-Navajas JM, et al., Interleukin 1 receptor signaling regulates DUBA expression and facilitates Toll-like receptor 9-driven antiinflammatory cytokine production. The Journal of experimental medicine. 2010; 207:2799-2807.
91. Xu G, et al., Ubiquitin-specific peptidase 21 inhibits tumor necrosis factor α-induced nuclear factor κB activation via binding to and deubiquitinating receptor-interacting protein 1. Journal of Biological Chemistry. 2010; 285:969-978.
92. Enesa K, et al., NF-κB Suppression by the Deubiquitinating Enzyme Cezanne A NOVEL NEGATIVE FEEDBACK LOOP IN PRO-INFLAMMATORY SIGNALING. Journal of Biological Chemistry. 2008; 283:7036-7045.
93. McNally RS, et al., DJ-1 enhances cell survival through the binding of Cezanne, a negative regulator of NF-κB. Journal of Biological Chemistry. 2011; 286:4098-4106.
94. Poalas K, et al., Negative regulation of NF-κB signaling in T lymphocytes by the ubiquitin-specific protease USP34. Cell Communication and Signaling. 2013; 11:25.
95. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis:an emerging feature of cancer. Nature Reviews Cancer. 2008; 8:835-850.
96. Niendorf S, et al., Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. Molecular and cellular biology. 2007; 27:5029-5039.
97. MacDonald E, Urbé S, Clague MJ. USP8 controls the trafficking and sorting of lysosomal enzymes. Traffic. 2014.
98. McCullough J, Clague MJ, Urbé S. AMSH is an endosome-associated ubiquitin isopeptidase. The Journal of cell biology. 2004; 166:487-492.
99. Clague MJ, Urbé S. Endocytosis: the DUB version. Trends in cell biology. 2006; 16:551-559.
100. Duex JE, Sorkin A. RNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis. Molecular biology of the cell. 2009; 20:1833-1844.
101. Duex JE, et al., Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. Journal of Biological Chemistry. 2011; 286:25377-25386.
102. Liu H, et al., Regulation of ErbB2 receptor status by the proteasomal DUB POH1. PloS one. 2009; 4:e5544.
103. Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nature Reviews Cancer. 2008; 8:387-398.
104. Tauriello DV, et al., Loss of the tumor suppressor CYLD enhances Wnt/β-catenin signaling through K63-linked ubiquitination of Dvl. Molecular cell. 2010; 37:607-619.
105. Zhao B, et al., The ubiquitin specific protease 4 (USP4) is a new player in the Wnt signalling pathway. Journal of cellular and molecular medicine. 2009; 13:1886-1895.
106. Huang X, et al., The COP9 Signalosome Mediates β-Catenin Degradation by Deneddylation and Blocks Adenomatous Polyposis coli Destruction via USP15. Journal of molecular biology. 2009; 391:691-702.
107. Ma P, et al., The Ubiquitin Ligase RNF220 Enhances Canonical Wnt Signaling through USP7-Mediated Deubiquitination of β-Catenin. Molecular and cellular biology. 2014; 34:4355-4366.
108. Jung H, et al., Deubiquitination of Dishevelled by Usp14 is required for Wnt signaling. Oncogenesis. 2013; 2:e64.
109. Lui TT, et al., The Ubiquitin specific protease USP34 regulates Axin stability and Wnt/β-catenin signaling. Molecular and cellular biology. 2011.
110. Tran H, et al., Trabid, a new positive regulator of Wnt-induced transcription with preference for binding and cleaving K63-linked ubiquitin chains. Genes & development. 2008; 22:528-542.
111. Pardali K, Moustakas A. Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2007; 1775:21-62.
112. Dupont S, et al., FAM/USP9x, a deubiquitinating enzyme essential for TGFβ signaling, controls Smad4 monoubiquitination. Cell. 2009; 136:123-135.
113. Al-Hakim A, et al., Control of AMPK-related kinases by USP9X and atypical Lys29/Lys33-linked polyubiquitin chains. Biochem. J. 2008; 411:249-260.
114. Wicks SJ, et al., The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-β signalling. Oncogene. 2005; 24:8080-8084.
115. Yeh HM, et al., Ubiquitin-specific protease 13 regulates IFN signaling by stabilizing STAT1. The Journal of Immunology. 2013; 191:3328-3336.
116. Zhang L, et al., Ubiquitin-Specific Protease 2b Negatively Regulates IFN-β Production and Antiviral Activity by Targeting TANK-Binding Kinase 1. The Journal of Immunology. 2014; 193:2230-2237.
117. McClurg UL, et al., Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway. Oncotarget. 2014; 5:7081.
118. Schröder C, et al., Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients. Journal of cancer research and clinical oncology. 2013; 139:1745-1755.
119. Wang SS, et al., Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proceedings of the National Academy of Sciences. 2014; 111:16538-16543.
120. Wang X, et al., The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death. Molecular pharmacology. 2014; 85:932-945.
121. Ke H, et al., Cyld inhibits melanoma growth and progression through suppression of the JNK/AP-1 and β1-integrin signaling pathways. Journal of Investigative Dermatology. 2012; 133:221-229.
122. Pannem RR, et al., CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis. 2013; bgt335.
123. Kim JM, et al., Inactivation of murine Usp1 results in genomic instability and a Fanconi anemia phenotype. Developmental cell. 2009; 16:314-320.
124. Williams SA, et al., USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell. 2011; 146:918-930.
125. Benassi B, et al., MYC is activated by USP2a-mediated modulation of microRNAs in prostate cancer. Cancer discovery. 2012; 2:236-247.
126. He X, et al., USP2a negatively regulates IL-1β-and virusinduced NF-κB activation by deubiquitinating TRAF6. Journal of molecular cell biology. 2013; 5:39-47.
127. Tao BB, et al., Up-regulation of USP2a and FASN in gliomas correlates strongly with glioma grade. Journal of Clinical Neuroscience. 2013; 20:717-720.
128. Nicassio F, et al., Human USP3 is a chromatin modifier required for S phase progression and genome stability. Current biology. 2007; 17:1972-1977.
129. Raychaudhuri P. USP3 controls BRCA1 "foci". Cell Cycle. 2014; 13:183.
130. Sharma N, et al., USP3 counteracts RNF168 via deubiquitinating H2A and gammaH2AX at lysine 13 and 15. Cell Cycle. 2014; 13:106-114.
131. Hock AK, et al., Regulation of p53 stability and function by the deubiquitinating enzyme USP42. The EMBO journal. 2011; 30:4921-4930.
132. Zhang L, et al., USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-[beta] type I receptor. Nature cell biology. 2012; 14:717-726.
133. Izaguirre DI, et al., PTBP1-dependent regulation of USP5 alternative RNA splicing plays a role in glioblastoma tumorigenesis. Molecular carcinogenesis. 2012; 51:895-906.
134. Nakajima S, et al., Ubiquitin-Specific Protease 5 Is Required for the Efficient Repair of DNA Double-Strand Breaks. PloS one. 2014; 9:e84899.
135. Oliveira AM, et al., USP6 (Tre2) fusion oncogenes in aneurysmal bone cyst. Cancer Research. 2004; 64:1920-1923.
136. Pringle LM, et al., Atypical mechanism of NF-κB activation by TRE17/ubiquitin-specific protease 6 (USP6) oncogene and its requirement in tumorigenesis. Oncogene. 2011; 31:3525-3535.
137. Ye Y, et al., TRE17/USP6 oncogene translocated in aneurysmal bone cyst induces matrix metalloproteinase production via activation of NF-κB. Oncogene. 2010; 29:3619-3629.
138. Chauhan D, et al., A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer cell. 2012; 22:345-358.
139. Cheon KW, Baek KH. HAUSP as a therapeutic target for hematopoietic tumors (review). International journal of oncology. 2006; 28:1209-1215.
140. Berlin I, et al., The deubiquitinating enzyme USP8 promotes trafficking and degradation of the chemokine receptor 4 at the sorting endosome. Journal of Biological Chemistry. 2010; 285:37895-37908.
141. Byun S, et al., USP8 is a novel target for overcoming gefitinib resistance in lung cancer. Clinical Cancer Research. 2013; 19:3894-3904.
142. Panner A, et al., Ubiquitin-specific protease 8 links the PTEN-Akt-AIP4 pathway to the control of FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. Cancer research. 2010; 70:5046-5053.
143. Xia R, et al., USP8 promotes smoothened signaling by preventing its ubiquitination and changing its subcellular localization. PLoS biology. 2012; 10:e1001238.
144. Schwickart M, et al., Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature. 2009; 463:103-107.
145. Wang S, et al., Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proceedings of the National Academy of Sciences. 2014; 111:4251-4256.
146. Cox JL, et al., The SOX2-Interactome in Brain Cancer Cells Identifies the Requirement of MSI2 and USP9X for the Growth of Brain Tumor Cells. PloS one. 2013; 8:e62857.
147. Peng J, et al., USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Diagnostic pathology. 2013; 8:177.
148. Sun H, et al., Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood. 2011; 117:3151-3162.
149. Sun C, et al., An azoospermic man with a de novo point mutation in the Y-chromosomal gene USP9Y. Nature genetics. 1999; 23:429-432.
150. Deng S, et al., Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast cancer research and treatment. 2007; 104:21-30.
151. Lin Z, et al., USP10 Antagonizes c-Myc Transcriptional Activation through SIRT6 Stabilization to Suppress Tumor Formation. Cell reports. 2013; 5:1639-1649.
152. Zeng Z, et al., Prognostic significance of USP10 as a tumor-associated marker in gastric carcinoma. Tumor Biology. 2014; 35:3845-3853.
153. Al-Salihi MA, et al., USP11 augments TGFβ signalling by deubiquitylating ALK5. Open biology. 2012; 2:120063.
154. Bayraktar S, et al., USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer journal (Sudbury, Mass.). 2013; 19:10.
155. Burkhart RA, et al., Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Molecular Cancer Research. 2013; 11:901-911.
156. de La Vega M, et al., The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility. Nature communications. 2011; 2:259.
157. Tian Z, et al., A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014; 123:706-716.
158. Shinji S, et al., Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. Oncology reports. 2006; 15:539-543.
159. Wu N, et al., Over-Expression of Deubiquitinating Enzyme USP14 in Lung Adenocarcinoma Promotes Proliferation through the Accumulation of β-Catenin. International journal of molecular sciences. 2013; 14:10749-10760.
160. Eichhorn PJ, et al., USP15 stabilizes TGF-[beta] receptor I and promotes oncogenesis through the activation of TGF-[beta] signaling in glioblastoma. Nature medicine. 2012; 18:429-435.
161. Inui M, et al., USP15 is a deubiquitylating enzyme for receptor-activated SMADs. Nature cell biology. 2011; 13:1368-1375.
162. Gelsi-Boyer V, et al., Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC cancer. 2008; 8:299.
163. Ernst A, et al., A strategy for modulation of enzymes in the ubiquitin system. Science. 2013; 339:590-595.
164. Ye Y, et al., Polyubiquitin binding and cross-reactivity in the USP domain deubiquitinase USP21. EMBO reports. 2011; 12:350-357.
165. McFarlane C, et al., The deubiquitinating enzyme USP17 is associated with nonsmall cell lung cancer (NSCLC) recurrence and metastasis. Oncotarget. 2013; 4:1836.
166. Liu LQ, et al., A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Molecular and cellular biology. 1999; 19:3029-3038.
167. Yan M, et al., Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling. Blood. 2007; 110:305-312.
168. Hassink GC, et al., The ER-resident ubiquitin-specific protease 19 participates in the UPR and rescues ERAD substrates. EMBO reports. 2009; 10:755-761.
169. Lee JG, et al., Characterization of the deubiquitinating activity of USP19 and its role in endoplasmic reticulumassociated degradation. Journal of Biological Chemistry. 2014; 289:3510-3517.
170. Li Z, et al., Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor. Biochemical and biophysical research communications. 2002; 294:700-709.
171. Yasunaga J, et al., Ubiquitin-specific peptidase 20 targets TRAF6 and human T cell leukemia virus type 1 tax to negatively regulate NF-κB signaling. Journal of virology. 2011; 85:6212-6219.
172. Riester M, et al., Integrative Analysis of 1q23. 3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clinical Cancer Research. 2014; 20:1873-1883.
173. Dai W, et al., Ubiquitin-Specific Peptidase 22, a Histone Deubiquitinating Enzyme, Is a Novel Poor Prognostic Factor for Salivary Adenoid Cystic Carcinoma. PloS one. 2014; 9:e87148.
174. Liang J, et al., Ubiquitin-specific protease 22: a novel molecular biomarker in glioma prognosis and therapeutics. Medical Oncology. 2014; 31:1-6.
175. Ning J, et al., Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with earlystage non-small cell lung cancer. European journal of histochemistry:EJH. 2012; 56.
176. Piao S, et al., Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral oncology. 2013; 49:796-801.
177. Schrecengost RS, et al., USP22 Regulates Oncogenic Signaling Pathways to Drive Lethal Cancer Progression. Cancer research. 2014; 74:272-286.
178. Wang H, et al., Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. Tumor Biology. 2013; 34:1635-1639.
179. Blount JR, et al., Ubiquitin-specific protease 25 functions in endoplasmic reticulum-associated degradation. PloS one. 2012; 7:e36542.
180. Zhong B, et al., Ubiquitin-specific protease 25 regulates TLR4-dependent innate immune responses through deubiquitination of the adaptor protein TRAF3. Science signaling. 2013; 6:ra35.
181. A Paduch D, Mielnik A, Schlegel PN. Novel mutations in testis-specific ubiquitin protease 26 gene may cause male infertility and hypogonadism. Reproductive biomedicine online. 2005; 10:747-754.
182. Stouffs K, et al., Possible role of USP26 in patients with severely impaired spermatogenesis. European journal of human genetics. 2004; 13:336-340.
183. Wang PJ, et al., An abundance of X-linked genes expressed in spermatogonia. Nature genetics. 2001; 27:422-426.
184. Martín Y, et al., USP29 controls the stability of checkpoint adaptor Claspin by deubiquitination. Oncogene. 2014.
185. Akhavantabasi S, et al., USP32 is an active, membranebound ubiquitin protease overexpressed in breast cancers. Mammalian Genome. 2010; 21:388-397.
186. Schulte I, et al., Structural analysis of the genome of breast cancer cell line ZR-75-30 identifies twelve expressed fusion genes. BMC genomics. 2012; 13:719.
187. Li Z, et al., Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein. Journal of Biological Chemistry. 2002; 277:4656-4662.
188. De Pittà C, et al., A leukemia-enriched cDNA microarray platform identifies new transcripts with relevance to the biology of pediatric acute lymphoblastic leukemia. haematologica. 2005; 90:890-898.
189. Paulsson K, et al., A novel and cytogenetically cryptic t (7; 21)(p22; q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specific protease gene USP42. Leukemia. 2005; 20:224-229.
190. Delgado-Díaz MR, et al., Dub3 controls DNA damage signalling by direct deubiquitination of H2AX. Molecular oncology. 2014.
191. Zeng LX, Tang Y, Ma Y. Ataxin-3 expression correlates with the clinicopathologic features of gastric cancer. Int J Clin Exp Med. 2014; 7:973-981.
192. Sacco J, et al., The deubiquitylase Ataxin-3 restricts PTEN transcription in lung cancer cells. Oncogene. 2013.
193. Switonski PM, et al., Mouse ataxin-3 functional knock-out model. Neuromolecular medicine. 2011; 13:54-65.
194. da Silva CG, et al., A20 ExprEssing Tumors And AnTicAncEr drug rEsisTAncE. 2014.
195. Skrott Z, Cvek B. Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. Mini reviews in medicinal chemistry. 2012; 12:1184-1192.
196. Schütz AK, et al., Role of CSN5/JAB1 in Wnt/β-catenin activation in colorectal cancer cells. FEBS letters. 2012; 586:1645-1651.
197. Pan Y, Yang H, Claret FX. Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer. Cancer biology & therapy. 2014; 15:256-262.
198. Rebbeck TR, et al., Modification of BRCA1-associated breast and ovarian cancer risk by BRCA1-interacting genes. Cancer research. 2011; 71:5792-5805.
199. Dexheimer TS, et al., Synthesis and Structure-Activity Relationship Studies of N-Benzyl-2-phenylpyrimidin-4-amine Derivatives as Potent USP1/UAF1 Deubiquitinase Inhibitors with Anticancer Activity against Nonsmall Cell Lung Cancer. Journal of medicinal chemistry. 2014; 57:8099-8110.
200. Okada K, et al., Vialinin A is a ubiquitin-specific peptidase inhibitor. Bioorganic & medicinal chemistry letters. 2013; 23:4328-4331.
201. Kessler BM. Selective and reversible inhibitors of ubiquitin-specific protease 7: a patent evaluation (WO2013030218). Expert opinion on therapeutic patents. 2014; 24:597-602.
202. Daviet L, Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie. 2008; 90:270-283.
203. D'Arcy P, et al., A Novel Small Molecule Inhibitor Of Deubiquitylating Enzyme USP14 and UCHL5 Induces Apoptosis In Myeloma Cells and Overcomes Bortezomib Resistance. Blood. 2013; 122:1923-1923.
204. Chen X, et al., Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and-independent mechanisms. Oncotarget. 2014; 5:p. 9118.
205. Mermerian AH, et al., Structure-activity relationship, kinetic mechanism, and selectivity for a new class of ubiquitin C-terminal hydrolase-L1 (UCH-L1) inhibitors. Bioorganic & medicinal chemistry letters. 2007; 17:3729-3732.
206. Mullally JE, et al., Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. Journal of Biological Chemistry. 2001; 276:30366-30373.
207. Altun M, et al., Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chemistry & biology. 2011; 18:1401-1412.